Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model

Although highly effective, BCR-ABL1 tyrosine kinase inhibitors do not target chronic myeloid leukemia (CML) stem cells. Most patients relapse upon tyrosine kinase inhibitor therapy cessation. We reported previously that combined BCR-ABL1 and BCL-2 inhibition synergistically targets CML stem/progenit...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Bing Z., Mak, Po Yee, Mu, Hong, Wang, Xiangmeng, Tao, Wenjing, Mak, Duncan H., Dettman, Elisha J., Cardone, Michael, Zernovak, Oleg, Seki, Takahiko, Andreeff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193504/
https://www.ncbi.nlm.nih.gov/pubmed/31371419
http://dx.doi.org/10.3324/haematol.2019.219261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193504/
https://www.ncbi.nlm.nih.gov/pubmed/31371419
http://dx.doi.org/10.3324/haematol.2019.219261

Ejemplares similares